Artemether

Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria[1].

Product Specifications

CAS Number

[71963-77-4]

Product Name Alternative

Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224

UNSPSC

12352005

Hazard Statement

H302

Target

Parasite

Type

Natural Products

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/artemether.html

Purity

99.20

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

C[C@H]1[C@@H](OC)O[C@@]2([H])[C@]34[C@@]([C@H](C)CC[C@]41[H])([H])CC[C@@](O2)(C)OO3

Molecular Formula

C16H26O5

Molecular Weight

298.37

Precautions

H302

References & Citations

[1]Xiao, S., et al., Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop, 2002. 82 (2) : p. 175-81.|[2]Wu, Z.P., et al., Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther, 2009. 8 (1) : p. 88-92.|[3]Wu H, et al. Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway. Cell Death Dis. 2018 May 1;9 (5) :498. |[4]Wang JX, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol. 2007 Mar;150 (5) :652-61.